Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.
HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequences may ultimately impact on the adherence to treatment of patients, eventually leading to treatment failure. Despite considerable advances in recent times, the pathogenesis of HALS remains elusive. Factors involved belong to three categories: those intrinsic to the host, some of them modifiable and some not, those associated with antiretroviral therapy, that are sometimes modifiable as well, and finally those related to HIV-1 infection and its consequences, most often not modifiable. The most commonly used strategies for HALS reversion have included host-dependent factors such as lifestyle and dietary modifications and antiretroviral-dependent factors such as switching or avoiding the use of drugs more prone to promote HALS. Lifestyle modifications and switching thymidine analogues have been associated with moderate success. Pharmacological interventions have included the use of insulin-sensitising agents and hormone therapy with disappointing results, whereas treatment with pravastatin or pioglitazone, and uridine supplementation seem to be associated with fat gain in preliminary studies. The only interventions with almost immediate results that may render a patient's appearance similar to his past one have included filling techniques for facial lipoatrophy and ultrasound-assisted liposuction for cervical fat pad hypertrophy. Among the filling options, semipermanent reabsorbable materials and autologous fat transfer have been associated with acceptable outcomes. As of now, the best hope should rely on the use of drugs friendly for fat, on defining the appropriate timing for starting antiretroviral and on continuing the research effort to understand the basic mechanisms underlying HALS pathogenesis. Only through this effort can the best chances for preventing or reverting established HALS be recognised.
del Mar Gutierrez
María
M
Autonomous University of Barcelona, Infectious Diseases Unit, Hospital de la Sant Creu i Sant Pau, Barcelona, Spain.
Mateo
Gracia
G
Domingo
Pere
P
D000273:Adipose Tissue / Q000473:pathology; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005145:Face / Q000473:pathology / Q000601:surgery; D039682:HIV-Associated Lipodystrophy Syndrome / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008019:Life Style; D015187:Lipectomy; D010349:Patient Compliance; D011788:Quality of Life / Q000523:psychology; D013518:Surgery, Plastic / Q000379:methods
D019380:Anti-HIV Agents